BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 26921100)

  • 41. Antibody therapy for acute lymphoblastic leukemia.
    Portell CA; Advani AS
    Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia.
    Silverman LB
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):259-264. PubMed ID: 29222264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.
    Advani AS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():131-7. PubMed ID: 24319174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
    Ruella M; Gill S
    Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
    Mahalleh M; Shabani M; Rayzan E; Rezaei N
    Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
    Kimble EL; Cassaday RD
    Leuk Lymphoma; 2021 Dec; 62(14):3333-3347. PubMed ID: 34402732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Research Advances in the Treatment of B-Cell Acute Lymphoblastic Leukemia Based on Surface Antigen Expression --Review].
    Su Y; Yin QS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):648-652. PubMed ID: 33812446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies.
    O'Dwyer KM; Liesveld JL
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):184-192. PubMed ID: 29050691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].
    Fu XH; Wang Y; Wang HJ; Wei SN; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang JX; Wang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):282-286. PubMed ID: 32447930
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    Lussana F; Gritti G; Rambaldi A
    J Clin Oncol; 2021 Feb; 39(5):444-455. PubMed ID: 33434063
    [No Abstract]   [Full Text] [Related]  

  • 57. Advances in T-cell therapy for ALL.
    Grupp SA
    Best Pract Res Clin Haematol; 2014; 27(3-4):222-8. PubMed ID: 25455270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adult Acute Lymphoblastic Leukemia.
    Paul S; Kantarjian H; Jabbour EJ
    Mayo Clin Proc; 2016 Nov; 91(11):1645-1666. PubMed ID: 27814839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
    Liu D; Zhao J; Song Y; Luo X; Yang T
    J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
    Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
    Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.